Overview

This book discusses specific immune cell regulatory  pathway(s), immune cell types,  or other mechanisms involved in host responses to tuberculosis that can be potentially targeted for host-directed therapy (HDT). The pathways/mechanisms investigated are either protective – thus calling for pathway/factor enhancing drugs – or maladaptive – thus calling for pathway/factor inhibitory drugs. Discovery and development (pre-clinical and clinical) of candidate HDT agents will also be elucidated, as well as approaches for HDT of other diseases. The benefit to the reader will derive from learning about the biology of multiple host pathways involved in health and disease, how these pathways are disrupted or dysregulated during tuberculosis, and which druggable targets exist in these pathways. This book provides the reader with a roadmap of current and future directions of HDT against tuberculosis. Since the host pathways/factors involved in protective or maladaptive responses to tuberculosis are not disease-specific, information learned from the context of tuberculosis likely will be relevant to other infectious and non-infectious diseases.

Full Product Details

Author:   Petros C. Karakousis ,  Richard Hafner ,  Maria Laura Gennaro
Publisher:   Springer Nature Switzerland AG
Imprint:   Springer Nature Switzerland AG
Edition:   1st ed. 2021
Weight:   0.688kg
ISBN:  

9783030569044

ISBN 10:   3030569047
Pages:   332
Publication Date:   04 December 2020
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Active
Availability:   Manufactured on demand  
We will order this item for you from a manufactured on demand supplier.

Table of Contents

Section 1: Introduction Chapter 1:           Introduction: An overview of host-directed therapies for tuberculosis Daniel Frank, Robert Mahon   Section 2: Targeting immunometabolism Chapter 2:           Sirtuin deacetylases: Linking Mycobacterial infection and host metabolism Lorissa Smulan, Hardy Kornfeld, and Amit Singhal Chapter 3:           The mammalian target of rapamycin complex 1 (mTORC1): an ally of M. tuberculosis in host cells Natalie Bruiners, Valentina Guerrini, Maria Laura Gennaro Chapter 4:           HIF-1α as a potential therapeutic target for tuberculosis treatment                                 Qingkui Jiang, Maria Laura Gennaro, Lanbo Shi Chapter 5:           Nuclear receptors in host-directed therapies against tuberculosis                                 Eun-Kyeong Jo   Section 3: Enhancing anti-mycobacterial mechanisms Chapter 6:           Autophagy as a target for host-directed therapy against tuberculosis                                 Surbhi Verma, Raman Deep Sharma and Dhiraj Kumar Chapter 7:           Metformin: a leading HDT candidate for TB                                 Amit Singhal and Hardy Kornfeld               Chapter 8:           Statins as host-directed therapy for tuberculosis Noton K. Dutta, Petros C. Karakousis Chapter 9:           Antimycobacterial attributes of mitochondria: An insight into host defense mechanisms Rikesh K Dubey, Apoorva Narain   Section 4: Targeting immune cells Chapter 10:        Conventional and unconventional lymphocytes in immunity against Mycobacterium tuberculosis                                 Paula Ruibal, Tom H.M. Ottenhoff, Simone A. Joosten Chapter 11:        Targeting inhibitory cells such as Tregs and MDSCs in the tuberculous granuloma Sadiya Parveen, John R. Murphy, and William R. Bishai Chapter 12:        Targeting suppressor T cells                                 Léanie Kleynhans, Gerhard Walzl Chapter 13:        Neutrophil-mediated mechanisms as targets for host-directed therapies against tuberculosis                                 Tobias Dallenga, Ulrich E. Schaible Chapter 14:         Type I interferon and interleukin-1 driven inflammatory pathways as targets for HDT in tuberculosis Katrin D. Mayer-Barber, Christopher M. Sassetti Chapter 15:        Mucosal-associated invariant and Vγ9Vδ2 T cells Charles K. Vorkas, Michael S. Glickman Chapter 16:        Airway epithelial cells Angélica M. Olmo-Fontánez, Jordi B. Torrelles   Section 5: Preclinical models for assessing HDTs Chapter 17:        In vitro models of human granuloma formation to analyze host-directed therapies Liku B. Tezera, Michaela T. Reichmann, Basim Al Shammari, Paul T. Elkington Chapter 18:        C3HeB/FeJ as a key mouse strain for testing host-directed therapies against tuberculosis Pere-Joan Cardona, Cristina Vilaplana Chapter 19:        The Rabbit Model for Assessing Host-Directed Therapies for Tuberculosis  Selvakumar Subbian, Gilla Kaplan   Section 6: Clinical trials of HDTs and special considerations for study endpoints Chapter 20:        Clinical trials of TB-HDT candidates Robert S. Wallis Chapter 21:        Outcomes for clinical trials of host-directed therapies for tuberculosis Akshay N. Gupte, Sara C. Auld, William N. Checkley, Gregory P. Bisson Chapter 22:        Pharmacological considerations for clinical trials of host-directed therapies for tuberculosis       Elisa H. Ignatius, Kelly E. Dooley

Reviews

Author Information

Petros C. Karakousis, M.D., is an infectious diseases-trained physician scientist and Professor of Medicine at the Johns Hopkins University School of Medicine. His research focus is on host-pathogen interactions contributing to Mycobacterium tuberculosis persistence and antibiotic tolerance. His laboratory is actively investigating the repurposing of clinically available agents with immune-modulatory properties as adjunctive host-directed therapy, in order to shorten the duration of TB treatment and improve lung pathology. Maria Laura Gennaro, M.D., is Professor of Medicine at Rutgers New Jersey School of Medicine. Her laboratory studies mechanisms of adaptation expressed by Mycobacterium tuberculosis and by the host macrophage during infection, with the goal of finding targets for therapeutic intervention. She has a specific interest in macrophage lipid metabolism, which is altered following M. tuberculosis infection, thereby promoting bacterial survival. Richard Hafner, M.D., is an infectious diseases-trained physician and Chief of the TB Clinical Research Branch in the Division of AIDS at NIAID/NIH. Throughout his career, he has had a long-standing interest in advancing innovative host-directed therapies for infections. He has been involved in several clinical trials, authored various articles, and hosted multiple scientific meetings related to research to develop targeted HDTs for TB.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions